GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (STU:VPA1) » Definitions » Float Percentage Of Total Shares Outstanding

AVEO Pharmaceuticals (STU:VPA1) Float Percentage Of Total Shares Outstanding : 99.70% (As of Jun. 07, 2024)


View and export this data going back to 2013. Start your Free Trial

What is AVEO Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AVEO Pharmaceuticals's float shares is 34.65 Mil. AVEO Pharmaceuticals's total shares outstanding is 34.76 Mil. AVEO Pharmaceuticals's float percentage of total shares outstanding is 99.70%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AVEO Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AVEO Pharmaceuticals's Institutional Ownership is 18.91%.

AVEO Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

AVEO Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=34.65/34.76
=99.70%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AVEO Pharmaceuticals (STU:VPA1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (STU:VPA1) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
SLGL IOBT OBSV CLNN RVLP ABOS SCPH PDSB CFRX CTXR OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
30 Winter Street, Boston, MA, USA, 02108
Website
https://www.aveooncology.com
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

AVEO Pharmaceuticals (STU:VPA1) Headlines

No Headlines